Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (Adriamycin) in doxorubicin-resistant P388 mouse leukaemia cells R. Ganapathi, A. Yen Doxorubicin (Adriamycin) and daunorubicin are two clinically important anthracycline antitumour drugs (Muggia & Rosencweig, 1983) . The development of acquired resistance to doxorubicin (DOX) and daunorubicin (DAU) is a serious problem associated with repeated courses of chemotherapy, and numerous studies have focussed on determining the characteristics of DOX-resistant and DAU-resistant cells and evaluating approaches to circumvent resistance (Dano, 1976; Ganapathi & Grabowski, 1983; Inaba & Johnson, 1978; Riehm & Biedler, 1972; Skovsgaard, 1980; Tsuruo et al., 1982) . In DOX-resistant and DAU-resistant tumour models, resistance to the cytotoxic effects of DAU and DOX has been suggested to be due to reduced cellular accumulation and/or retention of drug (Inaba et al., 1979; Skovsgaard, 1978) . The phenomenon of reduced cellular drug levels as a mechanism of resistance is substantiated by studies which have demonstrated that augmentation of cellular accumulation of DAU and DOX with Tween 80, calmodulin inhibitors and calcium antagonists can significantly enhance the cytotoxic response (Ganapathi & Grabowski, 1983; Inaba & Johnson, 198; Riehm & Biedler, 1972; Tsuruo et al., 1982) . The relationship, however, between cellular anthracycline levels and resistance is not true for the potent lipophilic anthracyclines, which are accumulated to a similar extent by DOX-sensitive and DOX-resistant cells (Ganapathi et al., 1984a) . Furthermore, since enhanced cytotoxicity in the presence of the calmodulin inhibitor trifluoperazine (TFP) is observed only with strong and not weak DNA binding antitumor agents (Ganapathi et al., 1984a; 1985a) Anti-tumour drug resistance when produced experimentally is usually carried to a high level, so that differences between the parental-sensitive and the resistant subline are maximized to enable identification of the mechanisms of resistance under optimal conditions (Frei, 1982; Wheeler et al., 1982) . The DOX-resistant (P388/DOX) P388 mouse leukaemia model system is >100-fold resistant to DOX, and mechanism(s) of resistance in this model may be different from those observed clinically. However, since the cellular pharmacokinetics of anthracyclines and the effect of TFP on the cytotoxicity of anthracylines have been extensively studied in P388/DOX cells, it represents a model system wherein a clearer understanding of the mechanism(s) of anthracycline resistance and scope for modulation, may be possible. Furthermore, the characteristics of DOX-resistance in P388/DOX cells, and the effects of TFP on cytotoxicity of DOX, have been observed in other progressively DOX-resistant tumour model systems in vitro and in vivo (unpublished observations). In the present study, using the P388/DOX cells, we demonstrate that although similar cellular DOX and DAU levels in the absence and presence of TFP can be achieved, perturbations in cell cycle traverse and cytotoxicity occur only with TFP treatment.
The source of P388/DOX cells and conditions for their maintenance in vitro are similar to those described earlier in detail (Ganapathi & Grabowski, 1983; Ganapathi et al., 1984a) . The P388/DOX cells in RPMI 1640 supplemented with 25mM N-2-hydroxy-ethylpiperazine-N-ethanesulfonic acid and 10% foetal bovine serum (FBS) were subcultured at a density of _0.1 x 106 cellsml-1, incubated at 37°C for 24 h, and subsequently used for the in vitro cytotoxicity studies. At initiation of drug treatment, cells were in log-phase at a density of -0.4 x 106 cells ml-1, and prior to plating in softagar, cell counts in control and treated cultures were not greater than 1.5 x 106cellsml-. In shortterm drug exposure studies, P388/DOX cells were treated for 3h and 6h with 0.5pgml-1 and 2.0 ,igml-1 of DOX in the absence and presence of 5 /pM TFP, washed, resuspended in drug-free medium, and incubated at 37°C in a humidified atmosphere of 5% CO2 plus 95% air for an additional 24h. Long term drug exposure studies involved continuous treatment of P388/DOX cells for 24h at 37°C in a humidified 5% CO2 plus 95% air atmosphere with O.l,ugml-P, 0.25ygml-' and 0.5jgml-1 of DAU and 0.25ugml-', 0.5 pgml-' and 1.0 yg ml-1 of DOX in the absence and presence of 5uM TFP. Specific studies carried out on control and treated P388/DOX cells were: (a) colony formation in soft-agar; (b) laser flow cytometry (FCM) for analysis of cellular DAU and DOX levels (only with cells treated for 24h); and (c) flow cytometric analysis of cellular DNA content for cell cycle phase distribution analysis.
Aliquots of control and treated (3 h, 6 h and 24 h) P388/DOX cells were washed twice with drug free RPMI 1640 supplemented with 10% FBS, and plated (1.5 x 104 trypan blue dye-excluding cells/Petri-dish) in triplicate in 35 x 10 mm Petridishes. Methodological details of the plating medium, incubation conditions and analysis of colony growth in the soft agar assay of P388/DOX cells are similar to those described earlier in detail (Ganapathi et al., 1984a) .
A Becton-Dickinson FACS-II cell sorter was used for FCM analysis of cellular DAU and DOX fluorescence (Ganapathi et al., 1984b; 1985b Cell cycle phase distribution analysis were carried out in a Becton-Dickinson FACS IV multiparameter cell sorter using propidium iodide stained nuclei of the cells. Briefly, control and treated cells were washed twice with ice-cold 0.85% sodium chloride solution and the cell pellet resuspended in hypotonic propidium iodide staining solution (Krishan, 1975) . The nuclei were maintained at 4°C for 24h in the staining solution prior to analysis for cell cycle traverse perturbations. At least 104 nuclei were analyzed in each sample, and the fraction of cells in G1, S, and G2 + M phases of the cell cycle determined as reported previously (Yen & Fairchild, 1982) .
Data on cellular DAU and DOX fluorescence, cell cycle phase distribution and survival in soft agar of P388/DOX cells treated with DAU and DOX in the absence and presence of TFP for 3 h, 6 h and 24 h are presented in Table I . Additionally, representative histograms of data in Table I , showing cellular DAU and DOX fluorescence profiles and the corresponding DNA distribution histograms with cell cycle phase distributions, following treatment of P388/DOX cells with DAU and DOX in the absence and presence of TFP for 24h are presented in Figure 1 . In P388/DOX cells treated with 5 UM TFP alone for 24h, survival was 100% of control, and although calmodulin inhibitors affect cell cycle traverse (Chafouleas et al., 1982) no changes in cell cycle phase distribution were apparent at the concentration of TFP used in this study. Cell to cell heterogeneity in DOX uptake based on FL/LS ratio, was apparent only in P388/DOX cells treated for 24h with 0.25pgml-' but not 0.5jgml-1 and 1.O0igml-1 DOX. In P388/DOX cells treated with DOX alone the enhancement in fluorescence intensity (based on the value of FL.PK.CH.) paralleled increases in doxorubicin concentration, but cell cycle phase distribution and survival in soft-agar was found to be independent of the extracellular DOX concentration and comparable to the untreated control. Similarly, in P388/DOX cells treated with DOX alone for 3 h and 6h no significant alterations in cell cycle traverse or cytotoxicity were observed. In contrast to these results, cellular DOX fluorescence, cell cycle traverse and survival in softagar were remarkably different in P388/DOX cells treated with DOX plus 5 gM TFP for 24 h. No cell to cell heterogeneity in cellular fluorescence was observed, and DOX fluorescence was -2-fold higher in TFP treated P388/DOX cells. In the presence of TFP, a reduction of cells in G1 and S phases of the cell cycle and a corresponding increase in G2 + M phase was evident with increases in DOX concentration. Furthermore, these perturbations in cell cycle traverse were accompanied by reductions in colony formation of (Ganapathi et al., 1984a) .
DOX-resistant cells are cross-resistant to DAU as well as lipophilic semisynthetic derivatives of DOX and DAU which differ in their cellular pharmacokinetics and binding properties to DNA (Ganapathi et al., 1985) . The results from the present study demonstrate, that in P388/DOX cells, at comparable cellular DAU or DOX levels, accumulation of cells in G2 phase of the cell cycle and a reduction in colony formation due to enhanced cytotoxicity occurs only in the presence of TFP. In an earlier study using FCM to analyze the effects of TFP on DOX levels in P388/DOX cells treated for 2h, it was observed that cell to cell heterogeneity in DOX fluorescence was apparent only in the absence of TFP. Based on these results, an enhanced cytotoxic effect with DOX in the presence of TFP was suggested to be due to a reduction in the heterogeneity of DOX accumulation (Ganapathi et al., 1984b) . Data from this study with P388/DOX cells treated for 24 h without TFP, indicates that cell to cell heterogeneity in DAU and DOX fluorescence is apparent only at the lower concentrations of 0.1 Mg ml-P1 DAU and 0.25 ug ml-P DOX. and DOX fluorescence was observed. Based on data in Figure 1 , it can be argued that enhanced cytotoxicity with DAU and DOX in the presence of TFP is due to higher cellular anthracycline accumulation. However, it is apparent from the results in Table I (Krishan & Frei, 1976) . Since the P388/DOX cells were treated continuously with DAU and DOX for 24 h, which is -2 cell cycle times, it appears that in the absence of TFP, the ability of the cells to overcome the G2 block may be a determinant of resistance. Induction of cell cycle traverse perturbations in P388/DOX cells treated with DAU and DOX in the presence of TFP, is unrelated to the antiproliferative effects of the calmodulin inhibitor, since no cytotoxicity or alterations in cell cycle phase distribution were observed with TFP alone. It is therefore possible, that in the presence of TFP, the P388/DOX cells are unable to overcome the damage induced by DAU and DOX, which result in cell cycle traverse perturbations and cytotoxicity. This is supported by some of our recent studies, where we have found that a reversal of DOX induced G2 block which parallels reduced cytotoxicity, does not occur in the presence of 5pM TFP (unpublished observations).
Resistance to DOX appears to be multifactorial (Ganapathi et al., 1984a; Kessel & Wilberding, 1985) since treatment with TFP does not restore DOX-sensitivity comparable to the parent-sensitive line. The results from this study demonstrating a lack of relationship between cellular DOX and DAU levels and cytotoxicity are also supported by the recent study of Chang and Gregory (1985) , wherein inherent resistance to DOX in pancreatic adenocarcinoma was found to be unrelated to cellular DOX levels. In summary, this study suggests, that the expression of resistance to the cytotoxic effects of DAU and DOX in DOXresistant P388 mouse leukaemia cells is unrelated to gross cellular drug levels, and that treatment with TFP (which may alter intracellular compartmentalization of DAU and DOX) results in the induction and expression of damage caused by DAU and DOX. Although membrane alterations have been implicated to mediate DOX-resistance by altering drug permeation (Kartner et al., 1983) , it appears that a delineation of the intracellular mechanism of action of DAU and DOX may greatly aid our understanding of the phenomenon of resistance to these clinically important DNAbinding anthracyclines. 
